Loading...

Anti–PD-1/PD-L1 therapy of human cancer

16,593 views

Loading...

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Mar 18, 2016

PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...